Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology Services
Globe Newswire•18/11/2026•08:44 ET
1
Key Highlights
- ➤Q3 revenue $2.89 million, versus none in Q3 2025
- ➤Operating income reached $2.0 million on $54,300 cost of revenue
- ➤Net income $33.6 million included a $25.26 million unrealized digital-asset gain
- ➤Digital assets totaled $142.4 million, or 93% of total assets
- ➤$10.5 million senior secured convertible note matures December 8, 2026, raising going-concern doubt
Expert Statements
Dr. Vin Menon, Chief Executive Officer of MindWave
“The third quarter marks a turning point for the Company, with our first meaningful revenue from technology services and operating income for the quarter”
Dr. Vin Menon, Chief Executive Officer of MindWave
“We have signed enterprise agreements across climate finance, sports media and insurance, all running on the same MindChain infrastructure.”
Dr. Vin Menon, Chief Executive Officer of MindWave
“Our focus now is delivering those projects on schedule, converting contracted work into recurring revenue and strengthening our balance sheet.”
Quarterly revenue of $2.89 million and operating income of $2.0 million as the company completes its transition to a technology infrastructure business
MATAWAN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), today reported financial results for the third quarter ended September 30, 2026, as filed in its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission.
Get started
Create a free account to read the full story.
